Session Information
Date: Monday, November 13, 2023
Title: (1345–1364) Reproductive Issues in Rheumatic Disorders Poster II
Session Type: Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Achieving remission is one of the treatment targets in the lupus care and it is also important in preventing the prevalence of adverse pregnancy outcomes (APO).
Although there are reports on relationship with LLDAS/DORIS remission and APOs, little is known on the relationship with Zen/Doria remission and APO, so we conducted this study. In addition, we aimed to investigate optimal cutoff glucocorticoid dosage to predict APO prevalence.
Methods: Pregnant with SLE who was followed up at two Japanese tertiary referral centers were included in our study. We divided the patients into two groups according to the achievement of Zen/Doria remission at conception and analyzed the APO prevalence. Furthermore, we investigated the optimal glucocorticoid dosage to minimize APO.
Results: Of the 124 pregnancies, 59 achieved Zen/Doria remission at conception. Baseline characteristics except for glucocorticoid dosage and hydroxychloroquine usage at conception did not differ according to the achievement of Zen/Doria remission. (remission vs not on remission; prednisolone (PSL): 4.0 [0.0, 5.0] mg/day vs 10.0 [8.0, 11.0] mg/day, p< 0.01, hydroxychloroquine: 54.2% vs 37.8%, p=0.14)
Pregnant on Zen/Doria remission showed significant decrease in the APO ratio compared with those without. (overall APO: OR 0.27, 95%CI 0.11-0.65, p< 0.01, maternal APO: OR 0.34, 95%CI 0.13-0.85, p=0.02, neonatal APO: OR 0.36, 95%CI 0.16-0.85, p=0.02, PROMISSE APO: OR 0.69, 95%CI 0.26-1.8, p=0.45)
On the other hand, glucocorticoid dose of prednisolone equivalent≥7.5mg/day at conception was associated with the increase in APO prevalence. (overall APO: OR 2.36, 95%CI 1.07-5.28, p=0.03, maternal APO: OR1.51, 95%CI 0.66-3.44, p=0.33, neonatal APO: OR 2.69, 95%CI 1.22-5.94, p=0.01, PROMISSE APO: OR 1.62, 95%CI0.68-3.89, p=0.28)
ROC curve also showed that prednisolone dosage >7.5mg/day was related to the decrease in live birth rate (AUC 0.68, 95% CI 0.50-0.85, sensitivity 0.77, specificity 0.62)
Conclusion: Achieving Zen/Doria remission can be a clinical target to reduce APOs in patients who wants to be conceived. In addition, if clinically feasible, reducing glucocorticoid dosage to less than 7.5mg/day before conception can be another treatment target.
To cite this abstract in AMA style:
Nakai T, Honda N, Fukui S, Kitada A, Yokogawa N, Okada M. Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/effect-of-zen-doria-remission-and-glucocorticoid-dosage-on-the-pregnancy-outcome-of-sle-retrospective-study-in-two-japanese-tertiary-referral-centers/. Accessed .« Back to ACR Convergence 2023
ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-zen-doria-remission-and-glucocorticoid-dosage-on-the-pregnancy-outcome-of-sle-retrospective-study-in-two-japanese-tertiary-referral-centers/